The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | CAR-HEMATOTOX risk stratification predicts hematological toxicity and infectious complications
Kai Rejeski, MD, LMU Munich, Munich, Germany, comments on two abstracts presented at the 2022 ASH Annual Meeting exploring the clinical utility of the CAR-HEMATOTOX (HT) risk stratification system in patients receiving various CAR-T cell therapies, including brexucabtagene autoleucel (brexu-cel), ciltacabtagene autoleucel (cilta-cel), and idecabtagene vicleucel (ide-cel). These multicenter retrospective analyses studied hematological toxicity, infectious complications and treatment outcomes, and it was demonstrated that HT score identified patients with a high-risk for prolonged neutropenia and higher incidence of infections. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Honoraria; Kite/Gilead: Other: Travel Support, Research Funding.
